Association of Interleukin-10 A-592C Polymorphism in Taiwanese Children with Kawasaki Disease by Hsueh, Kai-Chung et al.
INTRODUCTION
Kawasaki disease (KD) is an acute systemic vasculitis that
predominantly affects infants and young children. Coronary
artery lesions (CALs) develop in 20-25% of the patients, which
makes KD the leading cause of acquired heart disease in chil-
dren. The cause of this disease is unknown but generally beli-
eved to be an infectious agent (1). Many reports have noted
an abnormal immune response in the acute phase of this dis-
ease and increase in serum cytokines, such as interleukin (IL)-
1β , IL-2, IL-4, IL-6, IL-8, interferon (INF)-γ , and tumor necro-
sis factor (TNF)-α (2-5). These cytokines may mediate endo-
thelial damage and lead to coronary artery disease while also
producing the systemic signs of inflammation that charac-
terize the disease (6). Previous reports have shown blood IL-
10 levels were also elevated during the acute phase of KD (5,
7, 8). The elevated IL-10 levels decreased immediately after
intravenous immune globulin (IVIG) administration, and the
decrease was coincident with rapid improvement in inflam-
matory symptoms (8). However, the significance of increased
IL-10 levels observed in KD is not fully understood. IL-10 is
a major immunoregulatory cytokine and has a number of im-
munomodulating effects on the immune system. It is pro-
duced by many cell types, including T lymphocytes, B lym-
phocytes, monocytes, and macrophages (9). IL-10 suppresses
type 1 T helper lymphocytes by decreasing IL-2 and INF-γ
production (10, 11). It also inhibits certain functions of acti-
vated macrophages by downregulating the expression of MHC
class II antigens, and co-stimulatory molecules (12), and by
inhibiting production of proinflammatory cytokines such as
TNF-α , IL-1, IL-6, IL-8, and IL-12 (10, 13). Contrary to its
T cell and macrophage inhibitory actions, IL-10 enhances B
cell survival, proliferation, differentiation, and immunoglob-
ulin production (14). Levels of IL-10 production are critical
in immune regulation and control the balance between in-
flammatory and humoral responses. Various studies have con-
firmed the association of IL-10 with autoimmune and infec-
tious diseases (15).
The human IL-10 gene is located on chromosome 1 and has
been mapped to the junction between 1q31 and 1q32 (16).
The capacity for IL-10 production is correlated with the genet-
ic composition of the IL-10 locus. Genetic factors account for
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Association of Interleukin-10 A-592C Polymorphism in Taiwanese 
Children with Kawasaki Disease
Elevated serum levels of interleukin-10 (IL-10) have been reported in patients with
Kawasaki disease (KD). IL-10 reduces the inflammatory actions of macrophages and
T cells and it may play a significant role in the regulation of inflammatory vascular
damage associated with systemic vasculitis. The aim of this study was to examine
whether -592 IL-10 promoter polymorphism is a susceptibility or severity marker of
KD in Chinese patients in Taiwan. The study included 105 KD patients and 100 nor-
mal controls. Genotype and allelic frequencies for the IL-10 gene polymorphism in
both groups were compared. There were no significant between-group differences
in the genotype distribution of IL-10 A-592C gene polymorphism (P=0.08). How-
ever, the frequency of the -592*A allele was significantly increased in the patients
with KD compared with controls (71.9% vs. 61.0%, P=0.019). The odds ratio for
developing KD in individuals with IL-10 -592*A allele was 1.64 (95% confidence
interval, 1.06-2.52) compared to individuals with the IL-10-592*C allele. No signifi-
cant difference was observed in the genotype and allelic frequencies for the IL-10
A-592C polymorphism between patients with and without coronary artery lesions.
The IL-10-592*A allele may be involved in the development of KD in Taiwanese
children. 
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approximately 75% of the variation in IL-10 secretion capaci-
ty in humans, and these genetic differences contribute to dis-
ease susceptibility (17). The variation of IL-10 expression is
thought to be at the transcriptional level since mutations in
the IL-10 gene promoter sequence may alter specific transcrip-
tional activation and cytokine production (18). 
This study hypothesized that the IL-10 gene polymorphisms
have a measurable influence on KD susceptibility and contri-
bute to or reduce the occurrence of coronary artery lesions. To
test this hypothesis, inheritance of the IL-10 promoter poly-
morphism at position -592 in patients with KD, as well as
the association of the polymorphism with clinical complica-
tions of CALs, were examined.
MATERIALS AND METHODS
Subjects
We enrolled patients with KD from the Department of Pe-
diatrics at the China Medical University Hospital, Taichung,
Taiwan. The study group included 105 patients, all of whom
met the criteria proposed by the Japanese Kawasaki Disease
Research Committee (19). (See Table 1 for the numbers of
subject studied.) All patients were treated with IVIG (2 g/kg
infused over 8-12 hr) and oral aspirin (80-100 mg/kg/day).
Echocardiographs were obtained by the pediatric cardiolo-
gist before or within 2 weeks of IVIG administration. Coro-
nary artery lesions were diagnosed from the echocardiograms
using the criteria proposed by the Japanese Kawasaki Disease
Research Committee (19): coronary arteries were classified as
abnormal if the internal lumen diameter was ≥3 mm in chil-
dren younger than 5 yr old or ≥4 mm in children older than
5 yr old, if the internal diameter of a segment measured ≥1.5
times that of an adjacent segment, or if the coronary lumen
was clearly irregular. We also studied 100 unrelated healthy
children (62 males and 38 females, 0.4-7.0 yr old, mean age
=3.2 yr) who served as the control group. All blood samples
were drawn before IVIG therapy in the KD patient group.
Control samples were tested in parallel with patient samples.
The ethics committee of the China Medical University Hos-
pital Institutional Review Board approved the study, and writ-
ten informed consent was obtained from the parents of all
subjects.
Analysis of IL-10 A-592C polymorphism
The genomic DNA was prepared from peripheral blood
using a genomic DNA isolation reagent kit (Genomaker, Tai-
pei, Taiwan). The IL-10 A-592C genotype was determined
using a polymerase chain reaction (PCR)-restriction fragment
length polymorphism (RFLP) assay. The primers were for-
ward 5′ -CCTAGGTCACAGTGACGTGG-3′ and reverse
5′ -GGTGAGCACTACCTGACTAGC-3′ . This generated
a PCR product of 412 bp. PCR amplification was done in a
50-μ L reaction volume containing 100 ng of genomic DNA,
0.5 μ M of each primer, 0.2 mM/L deoxynucleotide triphos-
phates, 10 mM/L Tris-HCl (pH 8.3), 50 mM/L KCl, 1.5 mM/
L MgCl2, and 1.25 units of Taq polymerase (Perkin Elmer,
Foster City, CA, U.S.A.). The PCR amplification was per-
formed in a programmable thermal cycler (Gene Amp PCR
System 2400; Perkin-Elmer). PCR cycle conditions consist-
ed of an initial denaturation step at 95℃ for 5 min followed
by 35 cycles of 1 min at 94℃, 1 min at 60℃, 1 min at 72℃,
and a final extension at 72℃ for 6 min. The PCR products
were digested with restriction endonuclease RasI (New Eng-
land Biolabs, Beverly, MA, U.S.A.) and the digested DNA
fragments were separated by 3% agarose gel electrophoresis
and identified by ethidium bromide staining. In the presence
of the IL-10 -592*A allele, RasI cut the 412 bp PCR product
into two fragments of 236 and 176 bp, respectively.
Statistical analysis
The SAS Version 8.2 (SAS Institute Inc., NC, U.S.A.) with
chi-square test was used to compare the genotype and the
allelic frequency distribution of the IL-10 gene for patients
with KD and control subjects. A chi-square test was also used
to compare differences between patients with and without
coronary artery lesions. A value of P<0.05 indicated a signif-
icant difference between the tested populations. Associations
between variables in cases and control subjects were deter-
mined using the odds ratio and 95% confidence interval.
RESULTS
Characteristics of the study patients
The characteristics of the 105 KD patients studied are sho-
wn in Table 1. The sex distribution of the total KD patients
was a male/female ratio of 1.4:1, which is comparable to the
previous reports of KD male/female ratios ranging from 1.5
to 1.7:1.31 patients (30%) were identified as having coronary
artery lesions. Parents of all KD patients enrolled in the study
Number of patients 105
Age (yr) at time of diagnosis
Mean 3.1
Median 1.82
Range 0.2-7.5
Sex, number of patients
Male 61
Female 44
Coronary artery lesions, number of patients
Absent 74
Present 31
Table 1. Characteristics of the Kawasaki disease (KD) patients440 K.-C. Hsueh, Y.-J. Lin, J.-S. Chang, et al.
on a voluntary basis; therefore, the study population is not
representative of the true incidence of either KD or coronary
artery lesions in Taiwan.
Allele and genotype frequencies of IL-10 A-592C 
promoter polymorphisms
The frequencies of the genotype in the KD and control
groups are shown in Table 2. Among the 105 KD patients,
56 (53.3%) had IL-10 genotype AA, 39 (37.1%) had AC,
and 10 (9.6%) had CC. Among the 100 control subjects, 40
(40.0%) had genotype AA, 42 (42.0%) had AC, and 18
(18.0%) had CC. There were no significant differences in the
genotype distribution of IL-10 A-592C gene polymorphism
between the healthy control subjects and KD patients (P=
0.08). However, the frequency of the -592*A allele was signif-
icantly increased in the patients with KD compared with con-
trols (71.9% vs. 61.0%, P=0.019). The odds ratio for devel-
oping Kawasaki disease in individuals with IL-10-592*A
allele was 1.64 (95% confidence interval, 1.06-2.52) com-
pared to individuals with the IL-10 -592*C allele. The asso-
ciation of IL-10 A-592C gene polymorphism with coronary
artery lesions of KD was examined. Both genotype and allelic
frequencies were not statistically different between KD patients
with and without coronary artery lesions (Table 3).
DISCUSSION
Kawasaki disease is an acute, inflammatory, systemic vas-
culitis of unknown etiology that is often complicated by coro-
nary artery aneurysm. KD is currently thought to be an infec-
tious disease with immunologic manifestations that occur only
in genetically susceptible individuals (1). However, the genet-
ic background of patients with KD is mostly unknown. Cyto-
kines with polymorphic gene sequences are potential mark-
ers of disease susceptibility because their gene products are in-
volved in KD pathogenesis (2-7). This study provides evidence
for a genetic association between KD and the IL-10 gene. 
The level of IL-10, one of the anti-inflammatory cytokines,
is markedly elevated (as are various proinflammatory cytokines)
during the acute phase of KD. IL-10 reduces the inflamma-
tory response of monocytes/macrophages and inhibits cytokine
production by Th1 cells. On the other hand, IL-10 is a potent
stimulator for human B cells. The significance of increased
IL-10 level observed in KD is not fully understood. It may
contribute to the upregulation of humoral immune respons-
es (increased B cell activation and hypergammaglobulinemia
are observed during the acute phase of KD [20]) and to the
downregulation of acute inflammation arising from increased
levels of proinflammatory cytokines such as TNF-α (7). 
The genetic makeup of the IL-10 promoter can determine
the level of IL-10 secretion. The promoter of the IL-10 gene
has been shown to be highly polymorphic. Among the iden-
tified polymorphisms in the IL-10 promoter, three linked
single nucleotide polymorphisms (SNPs) (i.e., -1,082 G/A,
-819 T/C, and -592 A/C) have been shown to influence the
IL-10 gene expression (21). Several functional studies showed
that -592*A, -819*T, and -1,082*A alleles are associated with
low levels of IL-10 production (22-24). In addition, earlier
reports (23, 24) found complete linkage disequilibrium bet-
ween allele -819*C and allele -592*C and between allele-
819*T and allele -592*A. IL-10 gene polymorphisms, espe-
cially the IL-10 A-592C polymorphism, have been implicat-
ed in associations with disease outcome. The position -592 is
in an area containing putative binding sites for NF-IL-6 and
*P<0.05, significant.
IL-10, interleukin-10; KD, Kawasaki disease.
Kawasaki Normal 
Odds
patients controls
ratio P
no. (%)  no. (%)
(95% CI) 
(n=105) (n=100)
Genotype
AA 56 (53.3) 40 (40.0) 0.08
AC 39 (37.1) 42 (42.0)
CC 10 (9.6) 18 (18.0)
Allelic frequency
Allele A 151 (71.9) 122 (61.0) 1.64 (1.06-2.52) 0.019*
Allele C 59 (28.1) 78 (39.0)  
Table 2. Genotypes and allelic frequencies of IL-10 A-592 C pro-
moter polymorphism in KD patients and normal control subjects 
KD total (n=105)
P KD (CAL-) KD (CAL+) 
no. (%) (n=74) no. (%) (n=31)
Genotype 0.27
AA 42 (56.8) 14 (45.2)
AC 27 (36.5) 12 (38.7)
CC 5 (6.7) 5 (16.1)
Allelic frequency 0.12
Allele A 111 (75.0) 40 (64.5)
Allele C 37 (25.0) 22 (35.5)
Table 3. Genotypes and allelic frequencies of IL-10 A-592C pro-
moter polymorphism in KD patients with and without coronary
artery lesions
IL-10, interleukin-10; KD, Kawasaki disease; CAL, coronary artery lesions.
Southern British 
Alleles Taiwanese Japanese Chinese Korean Cau-
(28) from Hong (29) casians
Kong (27)   (23, 24)
-592A 0.61 0.672 0.67 0.62 0.21
-592C 0.39 0.328 0.33 0.38 0.79
Table 4. Allele frequencies of the interleukin-10 A-592C promoter
polymorphism among Taiwanese controls and other ethnic popu-
lationsInterleukin-10 Gene Polymorphism in Kawasaki Disease 441
STAT-1 (25). The -592*A allele has been associated with in-
creased incidence of sepsis and mortality in critically ill pati-
ents (26) and with renal involvement in SLE patients (27).
These results suggest the influence of the IL-10 A-592C poly-
morphism in disease progression and prognosis.
The prevalence of IL-10 -592*A allele varies from popu-
lation to population (Table 4), with the greatest rate found
in Japanese (67.2%) (28), southern Chinese from Hong Kong
(67%) (27), Korean (62%) (29), and British Caucasians (21%)
(23, 24). In our study of Chinese healthy subjects from Tai-
wan, the IL-10 -592*A allele frequency was 61.0%, which
is very similar to this frequency in Korean and Hong Kong
Chinese but markedly different from Caucasians. The distri-
bution of various genotypes for the IL-10 promoter polymor-
phic sites differ significantly between ethnic populations sug-
gesting that this could be a useful anthropologic genetic mark-
er. The frequency of the IL-10 -592* A allele was significant-
ly increased in our patients with KD, suggesting that it might
represent a candidate genetic marker to predict the develop-
ment of KD for an individual. 
Serum levels of an array of cytokines, including proinflam-
matory and anti-inflammatory cytokines, are elevated in pati-
ents with KD. Complex regulatory interactions exist to sup-
press ongoing inflammatory response. Regulation is often
achieved via parallel secretion of antagonistic cytokines and
soluble receptors. However, it is difficult to predict the net
contribution of inhibitory cytokines to an inflammatory res-
ponse by determination of serum levels. Furthermore, such
regulation is further complicated by the ratio of cytokine to
soluble receptor, such as TNF to sTNFR or IL-10 to sIL-10R,
within the local environment. Therefore, we speculated that
the relative lack of IL-10 compared with the elevated levels
of various proinflammatory cytokines may contribute to the
proinflammatory milieu in KD even though increased IL-10
level was observed during the acute phase of KD. Thus, the
fact that most Asians carry the IL-10 -592*A allele (which
is associated with low IL-10-secreting capacity) may partial-
ly explain why Kawasaki disease is most highly expressed in
Asian populations, mainly Japanese (30). Function-related
experiments and investigation to determine whether IL-10
-592*A allele is similarly associated with KD in subjects of
other ethnic origin would be intriguing and worthwhile.
Of interest, a recent study conducted in a Korean popula-
tion by Jin et al. (31) showed no significant difference in allele
or genotype frequency for the IL-10 -592 A/C polymorphism
between KD patients and control subjects but the study show-
ed a significantly higher frequency of the IL-10 -592 C allele
in KD patients with CALs. Although a relatively small sam-
ple size is a limitation of both our study and that by Jin et al.,
the inconsistent results may be due to environmental factors
and differences in the genetic backgrounds of the study pop-
ulations. Because KD appears to be a polygenic disease, and
a wide number of cytokines seem to be implicated in the reg-
ulation of vasculitis. It is apparently unlikely that the IL-10
-592 polymorphism is the only gene conferring susceptibil-
ity to KD and it remains formally possible that the associa-
tion may reflect linkage disequilibrium with polymorphisms
in currently uncharacterized genes. As a result, although the
distribution of IL-10 promoter polymorphisms is very simi-
lar in healthy controls from Taiwan and Korea, the other im-
portant immunogenetic differences in terms of disease suscep-
tibility and severity between patients from these two popu-
lations may also explain the discordant results observed in the
IL-10 gene polymorphism distribution.
We were unable to demonstrate a role of this polymorphism
in the predisposition of KD patients to the development of
CALs. There may be a number of reasons for this. First, the
number of patients with CALs was too small to determine a
significant association. Second, this polymorphism may sim-
ply not be involved in the genetic susceptibility to CALs. Thi-
rd, specific characteristics of disease pathology within KD,
such as CALs formation, may be associated with specific poly-
morphisms in a number of genes and may represent interact-
ing complex genetic traits. Thus, the role of IL-10 A-592C
polymorphism in the development of CALs may be apparent
only when it is examined in the context of the interaction of
other polymorphisms in or close to IL-10 gene or located in
other genes which are related to angiogenic and inflamma-
tory processes. 
The present study is somewhat limited by the relatively
small study population, the possibility of linkage disequilib-
rium with an unknown risk single nucleotide polymorphism
and the lack of function-related experiments. However, our
findings provide preliminary data suggesting that IL-10 -592
*A allele is associated with susceptibility to KD in the Tai-
wanese population. To establish firmly the relationship bet-
ween IL-10 promoter polymorphism and KD, further large-
scale studies are required in individuals of other ethnicities.
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